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Abstract
Most human seizures occur early in life, consistent with established excitability-promoting
features of the developing brain. Surprisingly, the majority of developmental seizures are not
spontaneous but are provoked by injurious or stressful stimuli. What mechanisms mediate
‘triggering’ of seizures and limit such reactive seizures to early postnatal life? Recent evidence
implicates the excitatory neuropeptide, corticotropin-releasing hormone (CRH). Stress activates
expression of the CRH gene in several limbic regions, and CRH-expressing neurons are
strategically localized in the immature rat hippocampus, in which this neuropeptide increases the
excitability of pyramidal cells in vitro. Indeed, in vivo, activation of CRH receptors – maximally
expressed in hippocampus and amygdala during the developmental period which is characterized
by peak susceptibility to ‘provoked’ convulsions – induces severe, age-dependent seizures. Thus,
converging data indicate that activation of expression of CRH constitutes an important mechanism
for generating developmentally regulated, triggered seizures, with considerable clinical relevance.
The majority of seizures occurring in the developing human are not spontaneous, that is,
they are not related to inherent abnormalities in the balance of neuronal excitation and
inhibition1. Rather, most seizures during infancy and childhood are provoked or triggered by
alterations in the normal milieu of excitable neurons2. Thus, rapid triggering by fever,
hypoxia or trauma provokes the majority of seizures in the infant and young child. These
seizures – a manifestation of rapid and transient enhancement of neuronal excitability in
response to adverse and potentially injurious agents – demonstrate an exquisite age
specificity (Table 1): febrile seizures are exclusive to infancy and early childhood1,2,
immediate traumatic seizures (as opposed to posttraumatic epilepsy) are far more common
in the young human compared with the adult, and anoxia-related seizures occur primarily in
the full-term neonate5,7. Other seizures that are not genetic in origin, such as infantile
spasms, which have been linked to a large number of injuries of the CNS and stressors that
include infections and malformations, are highly age specific and primarily restricted to the
first year of life6.
In the present review, we focus on novel and evolving concepts regarding potential
mechanisms for the rapid transduction of stressful alterations of neuronal milieu into
enhanced excitability and resulting seizures. We discuss the cascade of molecular events
triggered by ‘stress’, with an emphasis on the excitatory neuropeptide, corticotropin-
releasing hormone (CRH). Established and novel in vivo and in vitro evidence for the role of
CRH in enhancing excitation in key limbic circuits, particularly in the tri-synaptic
hippocampal pathway, are discussed. Finally, we describe recent data regarding the
receptors that mediate CRH-induced excitation, and provide the probable mechanisms
underlying the remarkable age specificity of the proconvulsant effects of this neuropeptide.
We conclude that CRH is a likely candidate for modulating excitability in response to
triggers such as fever, hypoxia or trauma, which result directly in developmentally
regulated, clinically important seizures.
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The dilemma: the immature brain is more excitable – but spontaneous
seizures, in the absence of prior injury, are uncommon
It is generally considered that the immature brain is more excitable than the adult brain (see
Ref. 8 for a recent review). This concept is supported in the human by the much greater
incidence of seizures in the infant and young child, as compared with the adult1,2,9.
Enhanced excitability and a higher sensitivity to proconvulsant agents have also been
demonstrated in immature experimental animals, including rats, cats and monkeys10,11.
Several characteristics of developing neuronal circuitry might account for this enhanced
excitability8,12. For example, GABA, the principal inhibitory neurotransmitter in the mature
CNS, has depolarizing, and thus excitatory, properties during the first postnatal week in the
rat12,13. In addition, excitatory amino acid receptors are both more abundant in the immature
brain14 and possess a subunit makeup that promotes neuronal depolarization15. These
factors are thought to contribute to an altered excitation–inhibition balance during
development8. At the circuit level, increased neuronal excitability is evident, leading, for
example, to the robust long-term potentiation observed during the second postnatal week
(‘infancy’ in the rat) in both hippocampal and cortical synapses16,17. In addition, the number
of cortical and hippocampal excitatory synapses is highest during this period and decreases
after the third post-natal week18. All of these factors favor enhanced excitation and a
propensity to generation and propagation of seizures8.
Although possessing enhanced intrinsic excitability and sensitivity to proconvulsant agents,
the immature brain is primarily engaged in normal neuronal functions. Indeed, the vast
majority of immature humans and rodents do not generate spontaneous seizures (although
experimental or other developmental injury can lead to reactive epilepsy at this age).
Surprisingly, even genetically determined spontaneous seizures (genetic epilepsies) typically
begin later than the ‘excitable’ developmental period19,20. During the neonatal and infancy
periods in the human, seizures are most commonly ‘triggered’, that is, they are induced by
acute and adverse alterations of the ‘normal’ neuronal milieu21. Thus, stressful
circumstances, such as trauma, anoxia, fever or hypoglycemia, lead rapidly (within minutes)
to enhanced excitability and seizures. Animal models of febrile convulsions3 and anoxic
seizures5 document the restricted period of susceptibility to these seizures in the rat, which is
confined to the second postnatal week3,22,23.
In summary, the immature brain is prone to seizures8, yet generation of seizures is selective:
spontaneous intrinsic and genetic seizures are relatively uncommon, while rapidly triggered
seizures can be provoked by diverse stressful signals.
Stressful signals activate the excitatory neuropeptide CRH
Candidate mechanisms for the rapid stress-induced excitation of limbic neurons emerge
from analyses of the molecular events induced by stress (Fig. 1). It has been well established
that the CNS responds to stressful circumstances by rapid hormonal, autonomic and
behavioral alterations, designed to enable survival in potentially adverse situations and
restore a steady state24,25. The major mediator of the hormonal and behavioral responses to
stress is the neuropeptide CRH (Refs 26,27). Within seconds of exposure to stress, CRH,
located in peptidergic neurons in the paraventricular hypothalamic nucleus (PVN), is
secreted from nerve terminals to influence rapid hormonal secretion from corticotrophs in
the anterior pituitary28,29 (Fig. 1A). In addition, stress upregulates transcription of the CRH
gene in the PVN within seconds30,31 (Fig. 2), leading to increased steady-state expression of
CRH-encoding mRNA (Refs 29,32).
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It has increasingly been recognized, however, that the actions of CRH as a neuromodulator
of stress are not confined to the neuroendocrine, hypothalamic–pituitary–adrenal system
(Fig. 1). Behavioral studies have demonstrated activation and arousal induced by this
peptide in a number of species27,33. These CRH-induced behaviors are indistinguishable
from behaviors observed under stressful circumstances34. Furthermore, administration of
CRH-receptor antagonists can abolish typical stress-induced behaviors35,36. Interestingly,
this blocking effect is demonstrable when the antagonists are injected into the amygdala,
suggesting that the site of stress-induced CRH-receptor activation lies at least partially
within this limbic region37 (Fig. 1B).
Studies of the distribution of CRH in the adult and developing CNS have demonstrated the
presence of significant populations of CRH-expressing neurons in discrete limbic
regions38,39. In particular, a large cluster of CRH-expressing neurons is located in the
central nucleus of the amygdala38,39. These cells are rapidly activated by stress to express
immediate–early genes40 and CRH-encoding mRNA (Refs 41,42). Stress-induced release of
CRH from these amygdala neurons is evident from microdialysis data and from local
infusion of competitive CRH-receptor antagonists37,43. CRH interacts with specific
postsynaptic G-protein-coupled receptors44–46 to alter intracellular cAMP levels.
Scattered CRH-immunoreactive neurons have also been localized to the hippocampal
formation of the adult rat38,47,48. Interestingly, recent detailed double-labeling and
ultrastructural studies in the hippocampal formation of the immature (10–13-day old),
unstressed rat have demonstrated a robust population of CRH-expressing GABAergic
interneurons49. Specifically, numerous, large CRH-immunoreactive neurons are found in
CA3 strata pyramidale and oriens, and fewer in the corresponding layers of CA1 and in
stratum lacunosum-moleculare of Ammon’s horn. In the dentate gyrus, CRH-
immunoreactive cell bodies are confined to the granule cell layer and hilus.
Ultrastructurally, CRH-expressing neurons have aspiny dendrites and their axon terminals
form axosomatic and axodendritic symmetric synapses with pyramidal and granule cells.
Other CRH-immunoreactive terminals were found to synapse on axon initial segments of
principal neurons. The vast majority of CRH-expressing neurons are co-immunolabeled for
the GABA-synthesizing enzyme isoforms GAD-65 and GAD-67 and most also contain
parvalbumin, but none were labeled for calbindin (Fig. 3). These findings establish the
presence of a significant, heterogeneous population of hippocampal CRH-immunoreactive
GABAergic interneurons. Furthermore, a subpopulation of neurons that express both CRH
and parvalbumin, located within and adjacent to the principal cell layers, consists of basket
and chandelier cells. Thus, axon terminals of these CRH-expressing interneurons are
strategically positioned to influence the excitability of the principal hippocampal neurons via
release of both CRH and GABA (Ref. 49).
In summary, the neuropeptide CRH functions within the hypothalamus to regulate rapid
hormonal responses to stress. However, the precise and selective distribution of CRH
neurons within the amygdala and hippocampus allows rapid release of this peptide to affect
the excitability of principal neurons and neuronal circuits within these key limbic regions.
What are the neurophysiological effects of CRH?
The actions of CRH on neurons have been investigated both in vivo and in vitro, in neuronal
populations as diverse as the locus coeruleus and cerebellum. For the purposes of this
review, we focus on limbic neurons and discuss in vivo and in vitro studies in the mature
and the developing rat.
In the adult rat in vivo, Ehlers et al. described long-latency (h) seizures induced by CRH,
with onset in the amygdala50, whereas Marrosu et al. recorded epileptiform discharges in the
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hippocampus after administration of CRH (Ref. 51). The long latency and behavioral
characteristics of CRH-provoked seizures in adult rats suggested that CRH might lower the
seizure threshold or act otherwise as a ‘kindling stimulus’ for the development of limbic
seizures52,53. Weiss et al. demonstrated that preadministration of CRH significantly
accelerated the development of stage 3 kindled seizures in mature male rats53. The duration
of after-discharge throughout the kindling process was significantly longer in the CRH-
pretreated animals. The data were interpreted to suggest a role for endogenous CRH in
limbic excitability and a mechanistic interaction with the kindling process.
In the neonatal and infant rat (first and second postnatal weeks, respectively), administration
of CRH into the cerebral ventricles leads to seizures within minutes54,55. The seizures, best
characterized on postnatal days 10–13, resemble other limbic seizures behaviorally56,57.
Using multiple bipolar depth electrodes, the earliest recorded epileptiform discharges
produced by CRH are detected in the amygdala55 and propagate to the hippocampus58. Both
the electrophysiological and the behavioral seizures provoked by CRH in the developing rat
persist for several hours59,60, and require doses (7.5 × 10−12 mol) that are 200 times smaller
than those required for generation of seizures in adults. Significantly, these doses of CRH,
by themselves, do not elevate the concentration of plasma corticosterone54, excluding the
possibility that glucocorticoids are involved in the initiation of CRH-produced seizures. This
is particularly important in view of the established effects of corticosterone, acting via
glucocorticoid-receptor activation, on Ca2+ currents in hippocampal CA1 pyramidal
neurons61. However, CRH-induced and other seizures constitute a stressful event, leading to
marked elevations of plasma corticosterone54, so that a later potentiation of hippocampal-
neuron excitability by glucocorticoids cannot be excluded. In addition, in vivo studies in the
immature rat indicate that, unlike in the adult, activation or blocking of CRH receptors does
not alter any measure of the acquisition or maintenance of kindling62,63.
CRH promotes excitability in hippocampal circuitry
Clearer insight into the effects of CRH on neuronal excitability has emerged from in vitro
studies. Intracellular electrophysiological recordings from hippocampal CA1 and CA3
pyramidal neurons of adult rat revealed that CRH increased the firing of CA1 pyramidal
neurons in response to excitatory input, and reduced afterhyperpolarization following an
action-potential train elicited by depolarizing current64. Similar findings were obtained in
the basolateral nucleus of the amygdala65.
In the immature rat (10–13 days old), field recordings demonstrated increased amplitudes of
population spikes elicited in CA1 after administration of CRH (Refs 66,67). These changes
were reversed with peptide wash-out and were prevented by preapplication of a CRH-
receptor blocker. Because of the high expression of CRH receptors in the CA3 pyramidal
cell layer68, whole-cell patch-clamp recordings were performed on hippocampal CA3
neurons. These studies (confirming the findings of Aldenhoff et al.64 in the adult)
demonstrated that CRH increased significantly the number of spikes elicited by depolarizing
current pulses. Thus, these findings indicate that, in the presence of a strong depolarizing
influence and action potential firing in the network, CRH can enhance excitability by
increasing the number of output action potentials of a given cell. CRH increased the
frequency of spontaneous excitatory postsynaptic currents (EPSCs) by an average of 252%
(Fig. 4A), but did not alter the amplitude or kinetic properties of miniature EPSCs,
indicating a lack of a direct postsynaptic effect of the peptide on AMPA-type glutamate
receptors. Similarly, CRH did not alter the amplitude of the pharmacologically isolated,
evoked monosynaptic glutamatergic currents. However, when the mossy fiber-evoked
responses were recorded from CA3 pyramidal cells in current-clamp mode in the presence
of bicuculline (Fig. 4B), CRH caused the appearance of large bursts of action potentials at
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variable latency. The bursts of action potentials appeared to be elicited by longer latency and
most likely polysynaptic EPSPs, in agreement with the observation that CRH increases the
firing of pyramidal cells elicited by a given excitatory input67.
Taken together, these data suggest that a given excitatory stimulus in the network can be
amplified by CRH, causing hyperexcitability, while in the absence of any other depolarizing
input, CRH does not lead to epileptiform neuronal activity (and seizures). However, the
peptide markedly enhances excitatory input (or spontaneous discharges) of CA3 pyramidal
neurons, with a robust increase in the numbers of spikes, consistent with hyperexcitability. It
should be noted, however, that the postsynaptic effects of synthetic CRH applied in the
hippocampal slice preparation might not fully represent the activation of CRH-expressing
interneurons. The latter is expected to generate the release of both endogenous CRH and
GABA, leading to a potentially different net influence on principal hippocampal cells.
Indeed, the neuroanatomical data showing CRH-immunoreactive interneurons synapsing on
the somata and axon initial segments of principal hippocampal neurons, combined with the
electrophysiological data discussed above, provide compelling evidence for the ability of
CRH to create an excitable state in the immature hippocampal circuit.
Support for the ability of CRH to enhance the excitability of the immature CNS in vivo is
provided by the finding that repeated infusions of CRH leads to a striking augmentation of
the convulsant potency of subsequently administered kainic acid69. A threshold kainic acid
dose, which resulted only in short bouts of automatisms in control rats, produced status
epilepticus in rats pretreated with CRH four times over two days. Other investigators have
shown that repeated amygdaloid seizures result in prolonged upregulation of expression of
the CRH gene in GABAergic interneurons in the dentate gyrus70. Thus, CRH-mediated
neuro-transmission might promote excitability and lead to limbic seizures, which, in turn,
increase the level of CRH at critical hippocampal synapses, further enhancing excitability in
a positive-feedback manner.
In conclusion, converging in vitro and in vivo data indicate that CRH might induce a
neuronal excitable state. In the presence of CRH-receptor activation, mild glutamatergic
input is amplified to result in epileptic discharges and, potentially, in seizures. It has been
established that CRH is secreted rapidly after stress in the hypothalamus and the amygdala,
and ongoing studies are focused on determining the effect of specific stressors on release of
CRH from hippocampal terminals. Thus, currently available data support a scenario in
which select stressful circumstances lead to rapid release of CRH, which transforms normal
glutamatergic excitatory input to amygdala and hippocampal neurons into epileptic output.
What are the postsynaptic mechanisms mediating CRH-induced
excitability? Why are the peptide’s effects most prominent in the
developing brain?
Specific G-protein-coupled receptors for CRH have been mapped to the adult46,71 and
immature rat limbic system68,72. Of the two characterized members of the CRH-receptor
family – CRF1 and CRF2 – selective non-peptide antagonists indicate that CRF1 activation
is required for the excitatory effects of the neuropeptide60. Both binding studies and receptor
type-specific in situ hybridization have shown that CRF1-receptor levels peak in the
hippocampus and the amygdala during development (postnatal days 6 and 9, respectively),
at 400–600% of adult levels68,73. The increased abundance of CRH receptors might partially
explain the potent proconvulsant effects of this peptide during the first weeks of life. Rapid
Ca2+ influx after application of CRH has been demonstrated in a variety of cell types,
including astrocytes, corticotrophs and neurons74–76. Administration of CRH has been
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shown to injure immature hippocampal CA3 and amygdala neurons77,78. In addition, recent
evidence points to a role for endogenous CRH in hippocampal neuronal death after
glutamate-receptor activation, ischemia or status epilepticus in the adult79–81, perhaps
contributing to the induction of pro-epileptic changes in neuronal excitability82. Taken
together, these data indicate that under circumstances leading to enhanced availability of
CRH at abundant CRF1-receptor sites in the immature hippocampus, the neuropeptide not
only enhances excitation but potentiates excitotoxicity in selected limbic circuits.
Conclusions: the significance of CRH to developmental seizures in the
human
The present review has focused on the potential role of CRH, a stress neurohormone, as the
key neuromodulator of triggered excitability in the developing brain. Many features of the
immature brain promote excitability, but the relative paucity of spontaneous seizures
suggests that a balance of excitation and inhibition exists during this period under steady-
state conditions. Perturbation of this balance by select injurious or stressful signals might
lead to seizures, via enhanced secretion of CRH, which acts on specific receptors in the
hippocampus and amygdala to promote excitability. CRH receptors in these regions are
maximally expressed during the time of peak CRH-induced excitability and of propensity to
triggered seizures, suggesting that regulation of expression of CRH receptors might play a
key role in modulating the ability of extrinsic signals to provoke limbic seizures. In human
infants, certain age-specific seizures respond to ACTH, a downregulator of CRH
synthesis83,84, and CRH-receptor antagonists increase seizure threshold in an animal model
of febrile seizures, the most common age-specific seizures of the developing human85,86.
These data further support the notion that selective blockers of CRH-receptor activation
might be useful anticonvulsants for age-specific, provoked seizures in the developing
human.
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Fig. 1. The neuroendocrine (A) and limbic (B) interactive, stress-activated corticotropin-
releasing hormone (CRH) loops
(A) Stress-conveying signals rapidly activate immediate–early genes in CRH-expressing
neurons of the central nucleus of the amygdala (ACe). Rapid CRH release in the ACe is
associated with CRH-expression in hypothalamic paraventricular nucleus (PVN) and
secretion of CRH into the hypothalamo–pituitary portal system, inducing ACTH and
glucocorticoid secretion from the pituitary and adrenal, respectively. Glucocorticoids exert a
negative feedback on the PVN (directly and via the hippocampus), yet activate expression of
the CRH gene in the amygdala, potentially promoting further CRH release in this region. (B)
CRH-expressing GABAergic interneurons (purple cells) in the principal cell layers of the
hippocampal CA1, CA3 and the dentate gyrus (DG) are positioned to control excitability of
the pyramidal and granule cells, respectively. These neurons might be influenced by stress-
evoked release of CRH from the ACe, via connections in the entorhinal cortex. For both
panels, red and blue arrows denote established or putative potentiating and inhibitory
actions, respectively. Arrows do not imply monosynaptic connections.
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Fig. 2. Rapid activation of expression of the corticotropin-releasing hormone (CRH) gene by
stress in the hypothalamic paraventricular nucleus
Coronal brain sections were subjected to in situ hybridization using an intronic probe
recognizing only heteronuclear RNA (hnRNA, unedited) encoding CRH. (A) Sections
derived from stress-free 9-day old pups, sacrificed within 20 s of disturbance, show little
CRH hnRNA-specific signal. (B) CRH expression is evident, by 2 min from the onset of
stress, and (C) peaks by 15 min. CRH hnRNA levels decline by 30 min from the onset of
stress (D), while total CRH-specific mRNA is increased for at least 4 h after stress29. Scale
bar in (A), 300 μm.
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Fig. 3. Distribution and characterization of corticotropin-releasing hormone (CRH)-expressing
neurons in the hippocampus
(A) Immunolabeled CRH-expressing neurons within and adjacent to the pyramidal (s.p.)
layer of CA3. (B) A double-labeled neuron, expressing both CRH (brown) and an isoform of
glutamic acid decarboxylase (GAD-65), the GABA-synthesizing enzyme (blue–green). (C)
An interneuron reacting with antibodies to both CRH (orange) and parvalbumin (plum red).
Scale bar, 50 μm in (A), 15 μm in (B) and 20 μm in (C). Abbreviations: s.o., stratum oriens;
s.r., stratum radiatum. Modified, with permission, from Yan et al.49
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Fig. 4. Corticotropin-releasing hormone (CRH) enhances excitability of hippocampal pyramidal
neurons
(A) Reversible increase in the frequency of spontaneous excitatory postsynaptic currents
with application of CRH (middle panel). Whole-cell recording of a CA3 pyramidal neuron
was performed in voltage-clamp mode (−60 mV). (B) Large, synchronized, variable-latency
discharges of CA3 neurons in current-clamp mode (in the presence of bicuculline) are
elicited by stimulation of mossy fibers in the presence of CRH. These action-potential
discharges are longer-latency, probably polysynaptic, excitatory postsynaptic potentials, and
are fully reversed when CRH is removed. Abbreviation: ACSF, artificial cerebrospinal fluid.
Modified, with permission, from Hollrigel et al.67
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TABLE 1
Provoked seizures occurring predominantly or exclusively during development
Seizure type Trigger Age specificity (human) Predominant/exclusive References for animal model
Febrile Fever Infants and young children Exclusive Baram et al.3
Holtzman et al.4
Hypoxic Decreased brain oxygenation Neonates Predominant Jensen et al.5
Infantile spasms Multiple (‘stressors?’) Infants Exclusive None, reviewed by Baram6
Trends Neurosci. Author manuscript; available in PMC 2012 June 11.
